Point-of-Care Testing


The patient and economic drivers for molecular point-of-care testing include: a positive impact on patient care and outcomes in time-critical clinical situations, improved antibiotic prescribing and stewardship to minimize antimicrobial resistance, and the potential to realize significant cost savings by optimized patient management and triage of patients to the most appropriate care settings.

The molecular point-of-care market opportunity extends well beyond the traditional boundaries of current molecular diagnostic competitors. The basis of competition and critical success factors in the molecular point-of-care market align favorably with the capabilities of our Validex System.


The molecular point-of-care testing market potential for Prominex targeted assays in sexually transmitted infections, respiratory infections, hospital acquired infections and blood stream infections is estimated to exceed $2 billion by 2020.